Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes

Research output: Contribution to journalJournal articlepeer-review

Standard

Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. / Tharp, William G.; Gupta, Dhananjay; Sideleva, Olga; Deacon, Carolyn F.; Holst, Jens J.; Elahi, Dariush; Pratley, Richard E.

In: Diabetes, Vol. 69, No. 2, 2020, p. 146-157.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Tharp, WG, Gupta, D, Sideleva, O, Deacon, CF, Holst, JJ, Elahi, D & Pratley, RE 2020, 'Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes', Diabetes, vol. 69, no. 2, pp. 146-157. https://doi.org/10.2337/db18-1163

APA

Tharp, W. G., Gupta, D., Sideleva, O., Deacon, C. F., Holst, J. J., Elahi, D., & Pratley, R. E. (2020). Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. Diabetes, 69(2), 146-157. https://doi.org/10.2337/db18-1163

Vancouver

Tharp WG, Gupta D, Sideleva O, Deacon CF, Holst JJ, Elahi D et al. Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. Diabetes. 2020;69(2):146-157. https://doi.org/10.2337/db18-1163

Author

Tharp, William G. ; Gupta, Dhananjay ; Sideleva, Olga ; Deacon, Carolyn F. ; Holst, Jens J. ; Elahi, Dariush ; Pratley, Richard E. / Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. In: Diabetes. 2020 ; Vol. 69, No. 2. pp. 146-157.

Bibtex

@article{038d0a57d11b4f4b8daec222b0db1145,
title = "Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes",
abstract = "Incretin hormone dysregulation contributes to reduced insulin secretion and hyperglycemia in patients with type 2 diabetes mellitus (T2DM). Resistance to glucose-dependent insulinotropic polypeptide (GIP) action may occur through desensitization or downregulation of beta-cell GIP receptors (GIP-R). Studies in rodents and cell lines show GIP-R expression can be regulated through peroxisome proliferator-activated receptor gamma (PPAR gamma) response elements (PPREs). Whether this occurs in humans is unknown. To test this, we conducted a randomized, double-blind, placebo-controlled trial of pioglitazone therapy on GIP-mediated insulin secretion and adipocyte GIP-R expression in subjects with well-controlled T2DM. Insulin sensitivity improved, but the insulinotropic effect of infused GIP was unchanged following 12 weeks of pioglitazone treatment. In parallel, we observed increased GIP-R mRNA expression in subcutaneous abdominal adipocytes from subjects treated with pioglitazone. Treatment of cultured human adipocytes with troglitazone increased PPAR gamma binding to GIP-R PPREs. These results show PPAR gamma agonists regulate GIP-R expression through PPREs in human adipocytes, but suggest this mechanism is not important for regulation of the insulinotropic effect of GIP in subjects with T2DM. Because GIP has antilipolytic and lipogenic effects in adipocytes, the increased GIP-R expression may mediate accretion of fat in patients with T2DM treated with PPAR gamma agonists.",
author = "Tharp, {William G.} and Dhananjay Gupta and Olga Sideleva and Deacon, {Carolyn F.} and Holst, {Jens J.} and Dariush Elahi and Pratley, {Richard E.}",
year = "2020",
doi = "10.2337/db18-1163",
language = "English",
volume = "69",
pages = "146--157",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association",
number = "2",

}

RIS

TY - JOUR

T1 - Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes

AU - Tharp, William G.

AU - Gupta, Dhananjay

AU - Sideleva, Olga

AU - Deacon, Carolyn F.

AU - Holst, Jens J.

AU - Elahi, Dariush

AU - Pratley, Richard E.

PY - 2020

Y1 - 2020

N2 - Incretin hormone dysregulation contributes to reduced insulin secretion and hyperglycemia in patients with type 2 diabetes mellitus (T2DM). Resistance to glucose-dependent insulinotropic polypeptide (GIP) action may occur through desensitization or downregulation of beta-cell GIP receptors (GIP-R). Studies in rodents and cell lines show GIP-R expression can be regulated through peroxisome proliferator-activated receptor gamma (PPAR gamma) response elements (PPREs). Whether this occurs in humans is unknown. To test this, we conducted a randomized, double-blind, placebo-controlled trial of pioglitazone therapy on GIP-mediated insulin secretion and adipocyte GIP-R expression in subjects with well-controlled T2DM. Insulin sensitivity improved, but the insulinotropic effect of infused GIP was unchanged following 12 weeks of pioglitazone treatment. In parallel, we observed increased GIP-R mRNA expression in subcutaneous abdominal adipocytes from subjects treated with pioglitazone. Treatment of cultured human adipocytes with troglitazone increased PPAR gamma binding to GIP-R PPREs. These results show PPAR gamma agonists regulate GIP-R expression through PPREs in human adipocytes, but suggest this mechanism is not important for regulation of the insulinotropic effect of GIP in subjects with T2DM. Because GIP has antilipolytic and lipogenic effects in adipocytes, the increased GIP-R expression may mediate accretion of fat in patients with T2DM treated with PPAR gamma agonists.

AB - Incretin hormone dysregulation contributes to reduced insulin secretion and hyperglycemia in patients with type 2 diabetes mellitus (T2DM). Resistance to glucose-dependent insulinotropic polypeptide (GIP) action may occur through desensitization or downregulation of beta-cell GIP receptors (GIP-R). Studies in rodents and cell lines show GIP-R expression can be regulated through peroxisome proliferator-activated receptor gamma (PPAR gamma) response elements (PPREs). Whether this occurs in humans is unknown. To test this, we conducted a randomized, double-blind, placebo-controlled trial of pioglitazone therapy on GIP-mediated insulin secretion and adipocyte GIP-R expression in subjects with well-controlled T2DM. Insulin sensitivity improved, but the insulinotropic effect of infused GIP was unchanged following 12 weeks of pioglitazone treatment. In parallel, we observed increased GIP-R mRNA expression in subcutaneous abdominal adipocytes from subjects treated with pioglitazone. Treatment of cultured human adipocytes with troglitazone increased PPAR gamma binding to GIP-R PPREs. These results show PPAR gamma agonists regulate GIP-R expression through PPREs in human adipocytes, but suggest this mechanism is not important for regulation of the insulinotropic effect of GIP in subjects with T2DM. Because GIP has antilipolytic and lipogenic effects in adipocytes, the increased GIP-R expression may mediate accretion of fat in patients with T2DM treated with PPAR gamma agonists.

U2 - 10.2337/db18-1163

DO - 10.2337/db18-1163

M3 - Journal article

C2 - 31757794

VL - 69

SP - 146

EP - 157

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 2

ER -

ID: 237103119